3909 |
Histopathological View of Bifurcation Lesion |
Aloke V. Finn |
Apr. 27. 19 |
3908 |
Clinically Relevant PeriProcedural MI: Practical and Clinical Trial Aspect |
Jung-Min Ahn |
Apr. 27. 19 |
3907 |
New Treatment Options for SGLT2 Inhibitor in Patients with Type 2 Diabetes |
Jung Ho Heo |
Apr. 27. 19 |
3906 |
Association of Lp(a) and Recurrent Ischemic Event After PCI |
Yong-Hoon Yoon |
Apr. 27. 19 |
3905 |
10-Year Follow-Up of MAIN-COMPARE Registry and Substudies |
Duk-Woo Park |
Apr. 27. 19 |
3904 |
TICA-KOREA: Ticagrelor Versus Clopidogrel in ACS Patients |
Osung Kwon |
Apr. 27. 19 |
3903 |
A Journey of PCSK9 Inhibitors: From Genetics To Clinics |
David Joel Cohen |
Apr. 27. 19 |
3902 |
The Benefit of Ezetimibe/Atorvastatin Combination in Coronary Patients Treatment |
Soo-Joong Kim |
Apr. 27. 19 |
3901 |
TAVR Low Risk Trials: Can It Be Standard? |
Alain G. Cribier |
Apr. 27. 19 |
3900 |
Evidence-based Optimal Bypass Surgery |
David Paul Taggart |
Apr. 27. 19 |